BMRN vs. RCKT

In the year-to-date period, BMRN achieves a -9.83% return, which is significantly higher than RCKT's -48.29% return. Over the past 10 years, BMRN has outperformed RCKT with an annualized return of -7.43%, while RCKT has yielded a comparatively lower -11.93% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Rocket Pharmaceuticals, Inc. (RCKT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMRN Sharpe Ratio is -0.66, which is higher than the RCKT Sharpe Ratio of -1.03. The chart below compares the historical Sharpe Ratios of BMRN and RCKT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BMRN nor RCKT has paid dividends to shareholders.

The maximum BMRN drawdown since its inception was -90.58%, roughly equal to the maximum RCKT drawdown of -94.90%. Use the drawdown chart below to compare losses from any high point for BMRN and RCKT. For additional features, visit the drawdowns tool.

The current volatility for BioMarin Pharmaceutical Inc. (BMRN) is 9.26%, while Rocket Pharmaceuticals, Inc. (RCKT) has a volatility of 32.59%. This indicates that BMRN experiences smaller price fluctuations and is considered to be less risky than RCKT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Rocket Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.